Kisspeptin vs PT-141: KISS1R and Melanocortin Receptor Signalling in Peptide Research

Kisspeptin and PT-141 Represent Different Peptide Signalling Systems

Both kisspeptin and PT-141 are peptide-based research compounds, but they have fundamentally different molecular targets and signalling pathways. Kisspeptin is involved in the KISS1/KISS1R signalling system which is linked to the hypothalamic regulation of gonadotropin-releasing hormone (GnRH), while PT-141, also known as bremelanotide, is a synthetic analogue of alpha-melanocyte-stimulating hormone and acts on melanocortin receptors.

The distinction is more helpful when it comes to experimental comparison than in trying to work out which compound is "better". Research into kisspeptin mainly focuses on neuroendocrine signalling via KISS1R and on its association with GnRH neurons, while research into PT-141 looks at melanocortin receptor signalling, specifically the pathways involving MC3R and MC4R.

The two compounds therefore have different places in the field of neuroendocrine research; although they are often mentioned together when talking about reproductive or sexual biology this does not mean that they are interchangeable from a pharmacological point of view.

Kisspeptin and the KISS1R Receptor

Kisspeptin is a group of peptides which are derived from the KISS1 gene and act on the kisspeptin-1 receptor, this receptor is generally known as KISS1R and has in the past been called GPR54.

KISS1R is a G protein-coupled receptor which is found in the neural circuits taking part in the regulation of the reproductive endocrine system. When this receptor is activated it can affect the activity of GnRH neurons, thus connecting kisspeptin signalling to the subsequent release of luteinising hormone and follicle-stimulating hormone.

The kisspeptin system is therefore of particular relevance to investigations looking into the way in which hypothalamic neurons communicate with the hypothalamic-pituitary-gonadal axis. Moreover, experimental research looks at how kisspeptin neurons integrate metabolic, hormonal and environmental signals before communicating with the GnRH-associated circuitry.

It is important in laboratory research to distinguish between the kisspeptin ligand activity and the subsequent endocrine measurements. For instance, a measured change in the levels of circulating gonadotropins is an indication of a downstream response and not a direct measurement of KISS1R activation.

PT-141, also known as bremelanotide, is a synthetic peptide similar to alpha-melanocyte-stimulating hormone; its pharmacological properties are linked to the melanocortin receptors, such as MC3R and MC4R.

Research into melanocortin signalling has shown that MC4R is a significant receptor in the neural circuits linked with sexual behaviour and autonomic function. Experiments have found MC4R to be present in a number of neural and peripheral tissues, thus providing a molecular basis for studying melanocortin pathways in various biological models.

The mechanism is therefore different from that of kisspeptin signalling. PT-141 does not work by directly activating KISS1R or by acting as a substitute for kisspeptin in the GnRH regulatory pathway; rather, the research centres on activation of melanocortin receptors and the neural signalling that occurs downstream of those receptors.

Comparing the Primary Molecular Targets

The main difference between the two peptides lies in the receptors to which they bind.

Kisspeptin is mainly useful as a model for studying KISS1R-mediated signalling and the relationship between kisspeptin neurons and GnRH neuronal circuits; PT-141 serves as a model for investigating melanocortin receptor activity, MC3R and MC4R being important receptor targets.

The way in which this difference is handled has an impact on the experimental design. For example, a study focusing on kisspeptin might measure KISS1R signalling, GnRH neuronal activity, the concentrations of LH or FSH, reproductive-axis feedback and other related endocrine variables. In contrast, a study involving PT-141 could look at melanocortin receptor activation, neuronal activity, behavioural endpoints or receptor distribution.

As a result, when these peptides are compared it is necessary to take into account the biological question under investigation rather than regard them as identical compounds.

Kisspeptin, GnRH and the Hypothalamic Signalling Network

One of the most thoroughly researched aspects of kisspeptin biology is the fact that it lies upstream of the GnRH neurons.

Kisspeptin neurons are able to give an excitatory input to GnRH neurons via KISS1R. Moreover, research has found neurons that express kisspeptin among neural groups containing neurokinin B and dynorphin, a group which is usually referred to as KNDy neurons. These interconnected signalling systems take part in the regulation of pulsatile GnRH activity and in the integration of endocrine feedback.

This provides a useful framework for experimental study of the way in which neural signals are converted into endocrine output. The researchers are able to look at changes at a number of levels, such as receptor signalling, neuronal activity, the release of GnRH and the levels of circulating gonadotropins.

It is important to note that these levels should not be regarded as equivalent measures. The fact that either LH or FSH has changed does not in itself indicate the exact intracellular mechanism which is responsible for the observed response.

PT-141 and Central Melanocortin Research

The research into PT-141 is based on a different neurobiological framework and has looked at melanocortin receptors since these receptors are widespread in the central nervous system and are associated with the neural circuits involved in sexual behaviour and autonomic regulation.

Preclinical studies have looked at the effects of activating melanocortin receptors in particular areas of the hypothalamus, such as the medial preoptic area, and experimental results have also shown a connection between melanocortin signalling and dopaminergic neural activity in various models.

These results show the reason why it is important to take into account the localisation of receptors in studies of PT-141. The biological response linked to a peptide may depend not only on its affinity for the receptor but also on the distribution of the receptor, the neural circuitry, the exposure to the ligand and the experimental model employed.

Kisspeptin and PT-141 Have Different Experimental Readouts

Since the peptides act via different receptor systems, researchers generally look at different primary and secondary endpoints.

Most studies on kisspeptin include endocrine measurements such as LH and FSH together with GnRH-related signalling. In some cases, the experiments also look at KISS1R expression, genetic variation, receptor function and the activity of the neuronal populations that express kisspeptin.

The studies on PT-141 have looked at melanocortin receptor activity, neuronal activation markers, receptor distribution and behavioural responses in experimental models. Previous preclinical research examined the changes in hypothalamic neuronal activity and sexual behaviour that occurred after melanocortin receptor stimulation.

The fact that the endpoints are different means that the results from one research system cannot be used automatically to deduce the activity in the other.

Human Research Provides Additional Context

Research involving both signalling systems has been carried out in humans, but the various studies have focused on different biological questions.

Studies on human kisspeptin have looked into the relationship between kisspeptin exposure and the secretion of reproductive hormones. Research that has been published has also looked at naturally occurring genetic variation in the KISS1, KISS1R genes and in other components of the GnRH pathway.

PT-141 has also been the subject of human research, this including controlled studies that looked at the physiological and subjective measures linked with sexual arousal. These studies form part of the clinical research record and must not be taken as indicating that research-grade peptide products are meant for use in humans.

When interpreting research, it is especially important to make the distinction between a clinical study that has been published on a specific pharmaceutical preparation and one involving an experimental research substance. Factors such as formulation, purity, identity, the study population, the exposure conditions and the analytical controls can all influence how the findings should be interpreted.

Peptide identity and Experimental Conditions Matter

Kisspeptin is not a single, uniform experimental substance; different isoforms of kisspeptin and peptide analogues have been studied, and variations in sequence length or amino acid substitutions can affect receptor activity and peptide stability. Recent reviews have still been devoted to the structural and functional diversity of the kisspeptin isoforms.

The principle is just as applicable in the case of PT-141: experimental conclusions must be tied to the particular peptide identity, the results of the analytical characterisation and the experimental conditions and not be generally applied to all materials referred to by a similar name.

Peptide identity, purity, concentration, storage conditions and analytical documentation are therefore important variables in connection with laboratory work. If these controls are not carried out, it will be difficult to assign differences between the results of the experiments solely to receptor pharmacology.

Receptor Selectivity Changes the Interpretation of Results

When it comes to comparing peptide signalling systems, receptor selectivity is also an important factor.

Kisspeptin research is closely linked to KISS1R, which is why receptor-specific assays are useful for determining whether a given response is one that is consistent with KISS1R-mediated activity. Genetic models and systems lacking the receptor can offer further information regarding pathway dependence.

Activity of PT-141 is observed among the various melanocortin receptor subtypes, and the MC4R has been the focus of considerable investigation in studies of its central pharmacology. It therefore follows that observations generally ascribed to 'melanocortin activity' may in fact involve more than one receptor subtype depending on the experimental system.

Receptor profiling can thus offer more informative data than depending on a single downstream endpoint.

Experimental Models Used in Kisspeptin Research

The biology of kisspeptin has been studied using molecular assays, cultured cells, neuronal preparations, animal models and human studies.

Cell-based experiments can be carried out in order to study KISS1R activation and intracellular signalling. Using animal models, researchers are able to look at the interactions between kisspeptin neurons, GnRH neurons and the wider endocrine system. Although human studies offer further information on endocrine responses they also include variables such as sex, age, reproductive status, hormonal state and genetic background.

These models address different questions; evidence from a receptor assay shows a pharmacological interaction under certain conditions, whereas an endocrine study looks at a much broader biological system.

Experimental Models Used in PT-141 Research

PT-141 has also been investigated in molecular, cellular, animal and human research systems.

Research in animals has looked at receptor expression, neuronal activation and the behavioural responses that occur after stimulating the melanocortin receptors. In humans, controlled experimental studies have been carried out to examine physiological and subjective measures.

It is important to take the differences between these models into account when interpreting the results. A response seen in a particular animal neural circuit cannot simply be assumed to indicate that the same mechanism is at work in humans. Similarly, a clinical endpoint does not necessarily show which receptor or intracellular pathway was responsible for the response.

Kisspeptin vs PT-141: Why the Comparison Is Mechanistic Rather Than Therapeutic

Kisspeptin and PT-141 may both be mentioned in connections with reproductive and sexual biology, but there is a considerable difference in their molecular pharmacology.

Kisspeptin serves as a research model for the regulation of GnRH neuronal signalling and the downstream endocrine pathways mediated by KISS1R. PT-141 acts as a model for investigating melanocortin receptor activity, especially within the neural circuits associated with MC3R and MC4R.

The appropriate comparison is not between the various peptides and the particular results they produce. Rather, it lies in the way two different peptide signalling systems interact with different receptors, neural circuits and experimental endpoints.

It also aids in making sure that the conclusions from one pathway are not wrongly applied to another.

Limitations in Current Kisspeptin and PT-141 Research

A big drawback in the study of peptides is the difficulty of telling direct receptor activity apart from the later biological effects.

The hormone levels of kisspeptin can show changes associated with various stages of the hypothalamic-pituitary-gonadal axis, and the observed response can be further affected by genetic variation, endogenous hormone feedback and the physiological state; studies relating to KISS1R variants show that receptor function can also vary considerably between different experimental systems.

The case of PT-141 is complicated by the distribution of its receptors and by the different activities of the various melanocortin receptor subtypes. Although studies on animal behaviour can yield some information about the mechanisms involved, behavioural endpoints are not direct indications of receptor activation.

It is also important to consider the stability of peptides and to carry out analytical characterisation; in fact, research into kisspeptin has shown that some of the kisspeptin forms are susceptible to proteolytic degradation and that modified analogues with different properties have therefore been developed.

The fact that these limitations exist means that peptide identity, receptor specificity, the experimental model and the endpoint all need to be assessed together.

Research Use Only

Direct SARMS supplies peptide materials for use in laboratory and analytical research. The information given in this article is for scientific and educational use and relates to published research on peptide structure, receptor signalling and experimental models.

Materials intended for research use are not to be consumed by humans or animals, nor are they to be used for the diagnosis, treatment, prevention or mitigation of disease. Human studies that have been published and which involve defined pharmaceutical preparations should not be taken as instructions or recommendations for the use of research materials.

FAQs

References

1. Xie Q, Kang Y, Zhang C, Xie Y, Wang C, Liu J, Yu C, Zhao H, Huang D. The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction. Front Endocrinol (Lausanne). 2022 Jun 28;13:925206. doi: 10.3389/fendo.2022.925206. PubMed ↗
2. Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014 Jul-Aug;20(4):485-500. doi: 10.1093/humupd/dmu009. Epub 2014 Mar 9. PubMed ↗
3. Gianetti E, Seminara S. Kisspeptin and KISS1R: a critical pathway in the reproductive system. Reproduction. 2008 Sep;136(3):295-301. doi: 10.1530/REP-08-0091. Epub 2008 May 30. PubMed ↗
4. Colledge WH. Kisspeptins and GnRH neuronal signalling. Trends Endocrinol Metab. 2009 Apr;20(3):115-21. doi: 10.1016/j.tem.2008.10.005. Epub 2008 Dec 25. PubMed ↗
5. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006 Jul;3(4):628-638. doi: 10.1111/j.1743-6109.2006.00268.x. PubMed ↗
6. Van der Ploeg LH, Martin WJ, Howard AD, Nargund RP, Austin CP, Guan X, Drisko J, Cashen D, Sebhat I, Patchett AA, Figueroa DJ, DiLella AG, Connolly BM, Weinberg DH, Tan CP, Palyha OC, Pong SS, MacNeil T, Rosenblum C, Vongs A, Tang R, Yu H, Sailer AW, Fong TM, Huang C, Tota MR, Chang RS, Stearns R, Tamvakopoulos C, Christ G, Drazen DL, Spar BD, Nelson RJ, MacIntyre DE. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11381-6. doi: 10.1073/pnas.172378699. Epub 2002 Aug 9. PubMed ↗
7. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006 Jul;3(4):628-638. doi: 10.1111/j.1743-6109.2006.00268.x. PubMed ↗